Evogene : Biomica Company Presentation

Microbiome-Empowered

Therapeutics

Dr. Elran Haber, CEO

January 2022

Forward-looking statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results

and/or other matters regarding or affecting Evogene Ltd. or its

subsidiaries, including Biomica Ltd. ("Biomica") (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Biomica claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties

which are difficult to predict and are not guarantees of

future performance. Therefore, actual future results, performance or achievements, and trends in the future of Biomica and Evogene may differ materially from what is expressed or implied by such forward- looking statements due to a variety of factors, many of which are beyond Biomica's and Evogene's control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information it files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors."

2

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirely by the previous statements. Except for any obligations to disclose information as required by applicable

securities laws, Biomica and Evogene disclaim any obligation or commitment

to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other

offering document, nor does it constitute or form part of any

invitation or offer to sell, or any solicitation of

any invitation or offer to purchase or subscribe

for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities

of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should

not be construed as an endorsement of the products or services of Evogene.

We are Biomica

An emerging biopharmaceutical company with cutting edge computational capabilities to develop the most optimized microbiome-based therapeutics.

Rooted in excellence		Breakthrough platform	Spearheading the future
Subsidiary of Evogene Ltd.		Drug candidates identified and	Optimized discovery, design &
(NASDAQ, TASE: EVGN), a pioneer		designed with PRISM - a proprietary	development, resulting in best-in-
in the field of applied		computational platform combining AI	class pharmaceuticals.
computational predictive biology,		capabilities with big data.	Precise & efficient - from concept
creating next-generation life
		to clinical trials in only 3 years.
sciences products.
3

Our Mission

To discover & develop novel therapies for microbiome-related human disorders.

We utilize computational predictive biology to provide new therapeutic modalities for high-value, unmet medical needs.

4

Showing promise in immune-mediated & infectious diseases

Current programs:

Immuno-oncology

Gastrointestinal (GI) related disorders

Antimicrobial resistance (AMR)

Harnessing the human microbiome

14
10	Trillions of microorganisms
live in & on our bodies
Play an essential role in
various daily bodily functions
Microbiome diversity is
associated with health &
wellbeing

microbes

in the

human body

5